These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
52 related articles for article (PubMed ID: 14002285)
1. [Studies on the production of sarcoma by the use of beryllium oxide]. YAMAGUCHI S Nagasaki Igakkai Zasshi; 1963 Feb; 38():127-38. PubMed ID: 14002285 [No Abstract] [Full Text] [Related]
2. [Experimental production of bone sarcomas in the rabbit by a single local injection of beryllium]. Mazabraud A Bull Cancer; 1975; 62(1):49-58. PubMed ID: 1063048 [TBL] [Abstract][Full Text] [Related]
8. Beryllium and growth. I. Beryllium-induced osteogenic sarcomata. HOAGLAND MB; GRIER RS; HOOD MB Cancer Res; 1950 Oct; 10(10):629-35. PubMed ID: 14778129 [No Abstract] [Full Text] [Related]
9. The influence of splenectomy on the induction of osteogenic sarcoma in rabbits. Janes JM J Bone Joint Surg Am; 1969 Oct; 51(7):1432. PubMed ID: 5258926 [No Abstract] [Full Text] [Related]
11. Bone sarcomas produced experimentally in the rabbit, using compounds of beryllium. SISSON HA Acta Unio Int Contra Cancrum; 1950 Jul; 7(1):171-2. PubMed ID: 14789605 [No Abstract] [Full Text] [Related]
12. Beryllium bone sarcomata in rabbits. BARNES JM; DENZ FA Br J Cancer; 1950 Jun; 4(2):212-22. PubMed ID: 14772368 [No Abstract] [Full Text] [Related]
13. [Experimental beryllium bone neoplasms as a model of osteogenic sarcoma]. Komitowski D Chir Narzadow Ruchu Ortop Pol; 1967; 33(2):237-42. PubMed ID: 5239633 [No Abstract] [Full Text] [Related]
14. Characterization of physicochemical properties of beryllium aerosols associated with prevalence of chronic beryllium disease. Stefaniak AB; Hoover MD; Day GA; Dickerson RM; Peterson EJ; Kent MS; Schuler CR; Breysse PN; Scripsick RC J Environ Monit; 2004 Jun; 6(6):523-32. PubMed ID: 15173904 [TBL] [Abstract][Full Text] [Related]
15. [Electron-microscopic studies on human and experimental osteogenic sarcoma]. KIKKAWA M Yonago Igaku Zasshi; 1962 Nov; 13():307-40. PubMed ID: 14032565 [No Abstract] [Full Text] [Related]
16. Measurement of beryllium in biological samples by accelerator mass spectrometry: applications for studying chronic beryllium disease. Chiarappa-Zucca ML; Finkel RC; Martinelli RE; McAninch JE; Nelson DO; Turteltaub KW Chem Res Toxicol; 2004 Dec; 17(12):1614-20. PubMed ID: 15606137 [TBL] [Abstract][Full Text] [Related]
17. Exposure pathway assessment at a copper-beryllium alloy facility. Day GA; Dufresne A; Stefaniak AB; Schuler CR; Stanton ML; Miller WE; Kent MS; Deubner DC; Kreiss K; Hoover MD Ann Occup Hyg; 2007 Jan; 51(1):67-80. PubMed ID: 16844720 [TBL] [Abstract][Full Text] [Related]
18. Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity. Zhou Z; Lafleur EA; Koshkina NV; Worth LL; Lester MS; Kleinerman ES Mol Cancer Res; 2005 Dec; 3(12):685-91. PubMed ID: 16380506 [TBL] [Abstract][Full Text] [Related]
19. Differences in dissolution behavior in a phagolysosomal simulant fluid for single-constituent and multi-constituent materials associated with beryllium sensitization and chronic beryllium disease. Stefaniak AB; Day GA; Hoover MD; Breysse PN; Scripsick RC Toxicol In Vitro; 2006 Feb; 20(1):82-95. PubMed ID: 16061346 [TBL] [Abstract][Full Text] [Related]
20. Historical analysis of airborne beryllium concentrations at a copper beryllium machining facility (1964-2000). McAtee BL; Donovan EP; Gaffney SH; Frede W; Knutsen JS; Paustenbach DJ Ann Occup Hyg; 2009 Jun; 53(4):373-82. PubMed ID: 19383942 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]